1. 1441PPhase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026. (23rd October 2018) Authors: Kawashima1, Y; Fukuhara, T; Furuya, N; Saito, H; Watanabe, K; Iwasawa, S; Tsunezuka, Y; Yamaguchi, O; Okada, M; Yoshimori, K; Nakachi, I; Gemma, A; Azuma, K; Hagiwara, K; Nukiwa, T; Morita, S; Kobayashi, K; Maemondo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1491PA phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial. (23rd October 2018) Authors: Kinoshita, I; Goda, T; Watanabe, K; Maemondo, M; Oizumi, S; Amano, T; Hatanaka, Y; Matsuno, Y; Nishihara, H; Asahina, H; Harada, T; Goto, K; Isobe, H; Nishimura, M; Dosaka-Akita, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 521PA randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). (24th November 2019) Authors: Baba, K; Tanaka, H; Fujita, Y; Nakamura, A; Kikuchi, E; Kawai, Y; Harada, T; Watanabe, N; Yokouchi, H; Usui, K; Saito, R; Watanabe, H; Masuda, T; Fukuhara, T; Kudo, K; Honda, R; Oizimi, S; Maemondo, M; Inoue, A; Morikawa, N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗